IN2013MU03069A - - Google Patents

Download PDF

Info

Publication number
IN2013MU03069A
IN2013MU03069A IN3069MU2013A IN2013MU03069A IN 2013MU03069 A IN2013MU03069 A IN 2013MU03069A IN 3069MU2013 A IN3069MU2013 A IN 3069MU2013A IN 2013MU03069 A IN2013MU03069 A IN 2013MU03069A
Authority
IN
India
Prior art keywords
extended period
time
topiramate
over
maintains
Prior art date
Application number
Other languages
English (en)
Inventor
Mandal Jayant
Maheshwari Deepak
Original Assignee
Ftf Pharma Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ftf Pharma Private Ltd filed Critical Ftf Pharma Private Ltd
Priority to IN3069MU2013 priority Critical patent/IN2013MU03069A/en
Publication of IN2013MU03069A publication Critical patent/IN2013MU03069A/en

Links

Landscapes

  • Medicinal Preparation (AREA)
IN3069MU2013 2013-09-25 2013-09-25 IN2013MU03069A (enrdf_load_stackoverflow)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN3069MU2013 IN2013MU03069A (enrdf_load_stackoverflow) 2013-09-25 2013-09-25

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3069MU2013 IN2013MU03069A (enrdf_load_stackoverflow) 2013-09-25 2013-09-25

Publications (1)

Publication Number Publication Date
IN2013MU03069A true IN2013MU03069A (enrdf_load_stackoverflow) 2015-07-17

Family

ID=54397116

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3069MU2013 IN2013MU03069A (enrdf_load_stackoverflow) 2013-09-25 2013-09-25

Country Status (1)

Country Link
IN (1) IN2013MU03069A (enrdf_load_stackoverflow)

Similar Documents

Publication Publication Date Title
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
PH12018501001A1 (en) Therapeutic compositions for treatment of human immunodeficiency virus
MX2019006878A (es) Uso de flecainida como un agente anti-conexina y metodo para potenciar los efectos de un farmaco psicotropico.
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EA201500742A1 (ru) Защищенные от нецелевого использования фармацевтические композиции
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
CO2017013317A2 (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma
PH12015500823A1 (en) Modified release formulations for oprozomib
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
EA201690974A1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
IN2013MU03069A (enrdf_load_stackoverflow)
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
PH12016502540B1 (en) Pharmaceutical dosage forms
EP3010534A4 (en) Pharmaceutical formulations and methods for oral delivery of biologically active ingredient
RS59133B1 (sr) Oblici doze za oralnu primenu aktivnih supstanci
EA201200799A1 (ru) Гепатопротекторное средство
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора